** Brokerage J.P.Morgan upgrades medical product maker Bioventus to "neutral" from "underweight", raises PT to $13 from $12
** Notes better visibility into co's growth; says co has taken steps in the right direction to stabilize and restore growth
** Says 2024 marked return to stability for co, with knee-therapy-related headwinds now lapped and fully in rearview and "pockets of strength" in areas including Ultrasonics
** Expects deals, while likely off the table for co in near to midterm future, could get investors confident in driving upside to numbers
** Says M&A has historically been a key factor in co's growth algorithm given its limited organic pipeline
** Also says the significant amount of debt in co's balance sheet could limit more strategic uses of capital
** Two of three brokerages rate the stock "buy", and one "hold"; with a median PT of $15
** Up to last close, stock has gained 112% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.